Had you stuck with his stock after Kozlowski was charged in 2002 you might now be richly rewarded.
Irish buyer offers a 26% premium to secure Cadence's Ofirmev injectable pain killer, which recently won approval in Canada.
Cadence sells an intravenous form of the painkiller acetaminophen used in hospitals.
After a weak October, biotech stocks have rebounded in a big way in November. The sector is on pace for an history year of absolute and relative performance.
Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
©1996-2017 TheStreet, Inc. All rights reserved.Action Alerts PLUS is a registered trademark of TheStreet, Inc.